Salute e Benessere

ONWARD ARC-EX® System Named One of TIME's Best Inventions of 2024

"We are grateful for TIME's recognition of the ARC-EX System, which has the potential to impact hundreds of thousands of people with spinal cord injury and impaired hand and arm function," said Dave Marver, CEO of ONWARD Medical. "SCI is a devastating injury that can change lives in an instant. We are hopeful ARC-EX Therapy is just the first of many innovative therapies ONWARD Medical can introduce for the benefit of the Spinal Cord Injury Community."TIME's annual list…
Nasdaq GlobeNewswire
31/10/2024

Amid Rising Costs, XRP Healthcare Prescription Savings Card Making a Difference…

While not a complete solution for financial pressures, the card delivers meaningful savings on repeat medications, especially for those managing chronic conditions like diabetes, high blood pressure, and mental health. While not a complete solution for financial pressures, the card delivers meaningful savings on repeat medications, especially for those managing chronic conditions like diabetes, high blood pressure, and mental health. "With financial pressures mounting, our Prescription...
PR Newswire
31/10/2024

Tiziana Life Sciences Announces Registered Direct Offering of up to…

Includes initial funding of approximately $5 million, as well as the option for additional proceeds of approximately $5 million In addition, the Company has issued the investor an option to acquire up to an additional 5,263,158 common shares at a price of $0.95 per share until the date that is 75 days from the date of the closing of the offering, resulting in additional gross proceeds of up to approximately $5 million, at the election of the investor.The Company intends to use the net...
Nasdaq GlobeNewswire
31/10/2024

Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting…

-New testing method highlights link between protofibrils and biomarkers for neurodegeneration- -Patient and caregiver perspectives on five-year treatment with lecanemab - - Utilization of blood biomarkers to predict brain amyloid accumulation in AHEAD study of preclinical AD-TOKYO and CAMBRIDGE, Mass., Oct.30, 2024(GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO:...
Nasdaq GlobeNewswire
31/10/2024

T-cell Malignancies Clinical Trial Pipeline Insights Featuring 70+ Companies |…

Key Takeaways from the T-cell Malignancies Pipeline Report Key Takeaways from the T-cell Malignancies Pipeline Report Request a sample and discover the recent advances in T-cell malignancy treatment drugs @ T-cell Malignancies Pipeline Report The T-cell malignancies pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage T-cell malignancy drugs, inactive and dormant assets, a comprehensive assessment of driving and...
PR Newswire
30/10/2024

Global Neurological Biomarkers Market to Surpass USD 16 Billion Mark by 2030 |…

Key Takeaways from the Neurological Biomarkers Market Report Key Takeaways from the Neurological Biomarkers Market Report To read more about the latest highlights related to the neurological biomarkers market, get a snapshot of the key highlights entailed in the Global Neurological Biomarkers Market Report Neurological Biomarkers Overview Neurological biomarkers are measurable indicators found in biological fluids, tissues, or images that reveal insights into the structure,...
PR Newswire
30/10/2024

Cellectis to Report Third Quarter 2024 Financial Results on November 4, 2024

Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the third quarter 2024 ending September 30, 2024 on Monday, November 4, 2024 after the close of the US market.The publication will be followed by an investor conference call and webcast on Tuesday, November 5, 2024 at 8:00 AM ET / 2:00 PM...
Nasdaq GlobeNewswire
30/10/2024

Galapagos Reports Third Quarter 2024 Financial Results and Provides Business…

We are advancing our pipeline and accelerating innovation through focused execution of ourForward, Fasterstrategy.We are committed to addressing the high unmet needs of patients through a growing cell therapy and small molecule pipeline with breakthrough potential. This includes more than 20 programs, with four assets in clinical development across 11 indications, and more than 15 preclinical programs in oncology and immunology. We achieved a major regulatory milestone with...
Nasdaq GlobeNewswire
30/10/2024

Inventiva announces the positive recommendation of the fifth DMC of the NATiV3…

The Data Monitoring Committee recommended to continue the clinical trial without modification of the current protocol, based on the pre-planned review of safety data. The recommendation was based on the unblinded review by the DMC of safety data from more than 1000 patients randomized in the main and exploratory cohorts, including over 800 and 170 patients that have been treated for more than 24 and 72 weeks, respectively. This fifth DMC review confirms the good safety profile of...
Nasdaq GlobeNewswire
30/10/2024

Invest Smart, Grow Fast! Industries with Up to 20% Annual Growth

1. Zero Net Energy Buildings: Global Markets The global market for Zero Net Energy Buildings (ZNEBs) - which produce as much energy as they consume - is experiencing rapid growth. In 2022, the market size was $42.8 billion, but it's expected to more than double to $109.2 billion by 2027. This represents an impressive annual growth rate of 20.6% over the next five years. As concern for climate change and energy efficiency continues to rise, the demand for ZNEBs is surging, driving innovation and…
PR Newswire
30/10/2024

RapidAI Applauded by Frost & Sullivan for Enhancing the Quality, Accuracy, and…

RapidAI offers an end-to-end portfolio of stroke imaging and assessment products for hospitals of all sizes. The Rapid platform leverages AI to generate high-quality, advanced images from non-contrast CT, CT angiography, CT perfusion, and magnetic resonance imaging diffusion and perfusion scans. This capability significantly enhances the speed and accuracy of time-critical triage or transfer decisions, leading to better patient outcomes. The company's diagnostic tool for large vessel occlusion…
PR Newswire
30/10/2024

Genetic Testing Services Market Size to be worth $12.48 Billion By 2031: The…

Read full market research report, "Genetic Testing Services Market Size, Share, and Growth Overview by 2031", published by The Insight Partners. Read full market research report, " Genetic Testing Services Market Size, Share, and Growth Overview by 2031 ", published by The Insight Partners. Regional Analysis - ByAsia Pacific genetic testing services market was valued atUS$ 646.31 millionin 2022 and is expected to reachUS$ 2,156.88 millionby 2030; it is estimated to...
PR Newswire
30/10/2024

Opioids Market Size to be worth $15.03 Billion By 2031: The Insight Partners

Read full market research report, "Opioids Market Size, Share, and Growth Overview by 2031", published by The Insight Partners. Read full market research report, " Opioids Market Size, Share, and Growth Overview by 2031 ", published by The Insight Partners. Overview of Report Findings Get Sample PDF Copy:https://www.theinsightpartners.com/sample/TIPRE00004770/ Market Segmentation Get Detailed Analysis:https://www.theinsightpartners.com/reports/opioids-market ...
PR Newswire
30/10/2024

At 25.8% CAGR Cell and Gene Therapy Market Size to Reach $28.05 Billion By 2031…

Read full market research report, "Cell and Gene Therapy Market Analysis and Forecast by Size, Share, Growth, Trends 2031", published by The Insight Partners. Read full market research report, " Cell and Gene Therapy Market Analysis and Forecast by Size, Share, Growth, Trends 2031 ", published by The Insight Partners. Overview of Report Findings Get Sample PDF Copy:https://www.theinsightpartners.com/sample/TIPRE00020854/ Market Segmentation Get Detailed...
PR Newswire
30/10/2024

Abzena Announces Major Expansion in Microbiology Laboratory Space in Support of…

The expansion of the QC microbiology lab is part of Abzena's broader strategy to help alleviate and address the market demand for quality testing which has been driven by increased regulatory requirements and provides a future-forward approach to streamlining biopharmaceutical innovations. The expansion of the QC microbiology lab is part of Abzena's broader strategy to help alleviate and address the market demand for quality testing which has been driven by increased regulatory requirements...
PR Newswire
30/10/2024

RAMSAY SANTE : Availability of the Universal Registration Document 2024

PRESS RELEASE Paris, 30 thOctober 2024 AVAILABILITY OF THE UNIVERSAL REGISTRATION DOCUMENT 2024 Ramsay Générale de Santé's 2024 Universal Registration Document was filed with the Autorité des marchés financiers (AMF) in ESEF format (European Single Electronic Format) on Wednesday 30 October 2024, under number D.24-0783. It is available to the public under the conditions provided for by the regulations in force and can be consulted on the Ramsay Santé website:www...
Nasdaq GlobeNewswire
30/10/2024

KFSHRC Contributes to Global Healthcare Innovation through Strategic…

RIYADH, Saudi Arabia, Oct.30, 2024(GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSHRC) continues to lead in medical innovation, advanced research, and education through strategic partnerships, enhancing patient care and significantly improving global patient outcomes.By collaborating with organizations such as King Abdullah University of Science and Technology (KAUST) and international teams from the UK, U.S, and India, which led to identifying the gene...
Nasdaq GlobeNewswire
30/10/2024

Signant Health and SPRIM PRO Align to Advance eClinical Solutions for…

"In our search for an eClinical technology partner, we prioritized finding an innovative and reliable solution that could adapt to our specialized research needs," said Susan Dallabrida, PhD, CEO of SPRIM PRO. "Signant's Unified Platform provides the flexibility and scalability we require to support our growing global operations, particularly in areas like infant nutrition studies where precision and reliability are paramount. At SPRIM PRO, more and more of the studies we conduct…
PR Newswire
30/10/2024

Alvotech to Report Financial Results for the First Nine Months of 2024 on…

Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, will release financial results for first nine months of the year ended September 30, 2024, after U.S. markets close on Wednesday, November 13, 2024, and will conduct a conference call with analysts to present the financial results and recent business highlights on Thursday November 14, 2024, at 8:00 am ET (13:00 GMT). Live audio of the conference...
Nasdaq GlobeNewswire
30/10/2024

Tiziana Life Sciences Announces Positive Results from Ozempic and Nasal Anti-CD3…

Key Highlights: Nasal anti-CD3 in combination with semaglutide demonstrates synergistic effects in promoting liver homeostasis in preclinical models of diet-induced obesity.The combination significantly reduces inflammation markers, a key factor in obesity-related metabolic disorders. Figure 1: Nasal anti-CD3 with Low and High Dose semaglutide promote Liver Homeostasis in DIOPBS= Placebo, HFD= High Fat Diet, LD= Low Dose, HD= High Dose, Sema= Semaglutide, aCD3= Study Version of...
Nasdaq GlobeNewswire
30/10/2024

SciBase initiates sales collaboration in Italy

Michelangelo Simonelli, CEO at Kilabs, is spearheading the introduction of Nevisense in Italy Under Simonelli's leadership leveraging on a team of recognized experts in the field such as Alessandro Cappella and Giuseppe Romano, Kilabs is working to integrate Nevisense into clinical practice, offering a more accurate and non-invasive method for early melanoma detection, which could significantly improve patient outcomes in the field of dermatology. This initiative underscores Kilabs' commitment…
PR Newswire
30/10/2024

Blue Earth Therapeutics Ltd announces completion of $76.5M Series A financing to…

"The establishment of PSMA-targeted radiopharmaceuticals as a class of therapy in prostate cancer represents a huge opportunity to improve outcomes for prostate cancer patients. Our new investors share our strong belief that Blue Earth Therapeutics' radiohybrid agents could be a significant improvement over currently approved treatment options," said Fulvio Renoldi Bracco, CEO of Bracco Imaging SpA. "The establishment of PSMA-targeted radiopharmaceuticals as a class of therapy in…
PR Newswire
30/10/2024

Numab Therapeutics Announces Initiation of Phase 1 Clinical Study of NM32…

NM32 is a first-in-class half-life-enhanced T-cell engager targeting ROR1, a tumor associated antigen with broad expression in solid tumors and hematological malignanciesLow molecular weight of NM32 allows to efficiently achieve higher tumor concentrations than larger immunoglobulin G molecules, the current standard format for CD3 engagers HORGEN, Switzerland, Oct.30, 2024(GLOBE NEWSWIRE) -- Numab Therapeutics AG (“Numab”) announced today the start of a Phase 1 clinical trial...
Nasdaq GlobeNewswire
30/10/2024

KFSHRC Leading Healthcare Innovation and Transformation in Saudi Arabia

RIYADH, Saudi Arabia, Oct.30, 2024(GLOBE NEWSWIRE) -- As Saudi Arabia advances its healthcare transformation journey, King Faisal Specialist Hospital & Research Centre (KFSHRC) is reshaping patient care, positioning the Kingdom as a global healthcare hub. With a nearly five-decade legacy in oncology, organ transplantation, and genetic medicine, KFSHRC has elevated healthcare standards and reduced the need for patients to seek treatments abroad.At the Global Health Exhibition 2024,...
Nasdaq GlobeNewswire
30/10/2024
Altri  Comunicati